Flaharty Asset Management’s Viking Therapeutics VKTX Stock Holding History

Flaharty Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,299	Closed	-$55.5K	–	476
2025 Q1	$55.5K	Buy	+2,299	New	+$72.7K	0.01%	207
2024 Q4	–	Sell	-256	Closed	-$16.2K	–	425
2024 Q3	$16.2K	Buy	+256	New	+$15K	﹤0.01%	282

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Flaharty Asset Management's VKTX Position: Q2 2025 in Review

Flaharty Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 2,299 shares — an estimated $55.5K sold.

Flaharty Asset Management first reported a position in VKTX in Q3 2024 and held it in 2 quarters. The position peaked at $55.5K in Q1 2025. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Flaharty Asset Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Flaharty Asset Management sold 2,299 Viking Therapeutics shares in Q2 2025, an estimated $55.5K.
Flaharty Asset Management first reported a position in Viking Therapeutics in Q3 2024 and held it in 2 quarters.
Flaharty Asset Management's Viking Therapeutics position peaked at $55.5K in Q1 2025.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Flaharty Asset Management's 13F filing for Q2 2025, filed 8 Aug 2025.